Related Experiment Video

Updated: May 28, 2026

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

Juvenile idiopathic arthritis - an update on pharmacotherapy

Philip Kahn1

  • 1New York University School of Medicine, NYU Langone Medical Center, New York, New York, USA. philip.kahn@nyumc.org

Bulletin of the NYU Hospital for Joint Diseases
|November 1, 2011
PubMed

Insights

Juvenile idiopathic arthritis (JIA) is a chronic childhood arthritis causing pain and deformity. Advances in targeted biologic therapies offer hope for safer, more effective treatments and potential cures for JIA.

Area of Science:

  • Pediatric Rheumatology
  • Immunology
  • Pharmacology

Background:

  • Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in children, leading to joint issues and growth impairment.
  • Extra-articular manifestations like uveitis and macrophage activation syndrome are critical therapeutic targets in JIA.
  • Limited non-specific treatments with significant side effects were available before the mid-1990s.

Purpose of the Study:

  • To review the clinical features of Juvenile idiopathic arthritis (JIA).
  • To provide updates on current and future pharmacotherapy for JIA.
  • To highlight advancements in understanding JIA biology for improved treatment.

Main Methods:

  • Literature review of clinical features and therapeutic advancements in JIA.
  • Analysis of historical and current pharmacotherapy for JIA.
  • Discussion of ongoing translational research and clinical trials in JIA.

Main Results:

  • JIA presents with diverse clinical manifestations and potential long-term complications.
  • Biologic therapies represent a significant advancement over older non-specific agents.
  • Understanding disease biology is crucial for developing targeted and safer JIA treatments.

Conclusions:

  • Current pharmacotherapy for JIA is increasingly tailored and effective due to targeted biologic agents.
  • Continued research into JIA pathogenesis holds promise for novel therapeutic strategies and potential cures.
  • Personalized medicine approaches are transforming JIA management.

Related Concept Videos

Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...